AYTU BIOPHARMA, INC 8-K

What Happened
Aytu BioPharma, Inc. (AYTU) filed a Form 8-K on January 20, 2026 disclosing that it held an investor meeting that day and issued a press release titled “Aytu BioPharma Recaps Investor Day Held on January 20, 2026.” The company posted the investor presentation used at the meeting to its investor website; the materials include information on the EXXUA™ (gepirone) extended‑release tablets opportunity. The press release is furnished as Exhibit 99.1 and the presentation as Exhibit 99.2 to the 8‑K.

Key Details

• Investor Day and related press release dated January 20, 2026; materials furnished on Form 8‑K (Exhibits 99.1 and 99.2).
• Presentation posted at https://investors.aytubio.com/ under Events & Presentations and includes discussion of EXXUA (gepirone) extended‑release tablets.
• The disclosure was furnished under Regulation FD and the company states the press release and presentation are not “filed” for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings unless explicitly stated.
• No financial results, executive changes, or material agreements were reported in this 8‑K (items relate to Regulation FD disclosure and exhibits).

Why It Matters
This 8‑K provides investors with the company’s most recent strategic and product‑pipeline update, specifically on the EXXUA (gepirone) extended‑release tablets opportunity, which could affect how investors value Aytu’s product pipeline. Because the materials are furnished (not filed), they are intended as timely public disclosures under Reg FD but are not treated as formal filed SEC statements or incorporated into other filings unless the company says so. Investors looking for material financial or governance changes should note this filing is an informational presentation rather than a report of results or corporate actions.